What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Tuberculoses
- Main trialPhase 2
- “A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis”In the company’s words, NCT07073638 on ClinicalTrials.gov
Other drugs for Pulmonary Tuberculoses
- SudapyridineShanghai Jiatan Pharmatech Co., Ltd · Phase 3
- QTP101Quratis Inc. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 15 Sep 2026 | Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026